The Role of Patient and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System

In this meta-analysis, researchers found that oral and topical minoxidil treatments for androgenetic alopecia had similar efficacy in improving hair density and diameter, but oral minoxidil resulted in a higher incidence of hypertrichosis compared to topical use.

In this study, researchers found no evidence of increased prevalence of pericardial effusions in alopecia patients treated with low-dose oral minoxidil compared to those not receiving minoxidil, based on point-of-care ultrasound evaluations.

This case report highlights a rare instance of minoxidil-induced pleuro-pericardial effusion with tamponade in a patient with end-stage renal disease on hemodialysis, which improved following pericardiocentesis and discontinuation of the drug.

This study highlights the complex clinical issues associated with using low dose oral minoxidil for alopecia, emphasizing the need for careful cardiology-dermatology collaboration due to rare but serious cardiovascular risks, especially in patients with existing cardiorenal or cardiovascular concerns.

This review discusses the emerging evidence for low-dose oral minoxidil in treating various types of alopecia, without providing new clinical results.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.

This article discusses the challenges of treating lichen planopilaris, reviews various therapeutic options including minoxidil, and reports no new clinical findings.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study found that 78% of patients continued taking oral minoxidil for androgenetic or traction alopecia, with 33% reporting decreased hair shedding and 28% noting increased scalp hair.

Minoxidil can cause dangerous fluid buildup around the heart.

Minoxidil, propranolol, and furosemide effectively control severe hypertension, but may cause sodium retention.